AviadoBio Presents New Safety and Biomarker Data from the Phase 1/2 ASPIRE-FTD Trial at the International Conference on Frontotemporal Dementias
Evolving biomarker data show early signs of dose-dependent increase in cerebrospinal fluid (CSF) progranulin Serum neurofilament light chain (NfL) at/below baseline in all patients with 52-week data AVB-101 continues to be well tolerated, with no serious adverse events related to treatment to date and no immunosuppression required LONDON — AviadoBio, a pioneering gene therapy company […]
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
